[March 18, 2021 in Shanghai, China] Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH; 02196.HK) announced that its subsidiary YaoPharma Co., Ltd. ("YaoPharma") had recently received the approval from the NMPA regarding the clinical trial for the YP01001 capsules (the “Investigational New Drug”) for the treatment of advanced solid tumors.
Macau plans to purchase a total of 400,000 doses (including the 105,000 doses granted the Special Import Authorization) COVID-19 mRNA vaccine BNT162b2 for the local COVID-19 vaccination program.
Recently, Jiangsu Wanbang Biopharmaceuticals Co., Ltd. ("Wanbang Biopharma") received marketing approval for Ticagrelor Tablets (Wansujie®) and Apixaban Tablets (Keyue®) from NMPA. The marketing of these two products will help solve more anti-thrombotic needs in clinical practice, benefit more patients, and enrich the product pipeline layout and enhance the product power of Wanbang Biopharma.
On February 2, 2021, Wanbang Biopharma's Empagliflozin Tablets, the new generation oral sodium-glucose co-transporter-2 (SGLT2) inhibitor, was approved by NMPA (Approval No.: GYZZ H20213115) for glucose control in patients with type 2 diabetes alone or in combination with metformin or metformin and sulfonylureas.
Shanghai, China, Jan, 29th, 2021 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the filing of clinical trial for HLX04-O, a recombinant anti-VEGF humanized monoclonal antibody ophthalmic injection, for the treatment of wet age-related macular degeneration (wAMD) has been approved by the Therapeutic Goods Administration, Australia. The Phase 3 clinical study of the project in Australia is intended to be initiated in the near future.
“We are excited and encouraged that COMIRNATY® has been authorized to emergency use in Hong Kong. This is an important milestone in the joint efforts of BioNTech and Fosun Pharma to achieve vaccine accessibility globally.
TROP2 (Trophoblast cell-surface antigen 2) is overexpressed in triple-negative breast cancer, non-small cell lung cancer, urothelial cancer and several other types of solid tumours, potentially to become a druggable target with a broad coverage of different types of tumours in various drug modalities including antibody-drug conjugates (ADC), bispecific antibodies and combination therapies.
HLX15 is a fully human anti-CD38 IgG1κ monoclonal antibody independently developed by Henlius. On one hand, HLX15 can directly bind to CD38 expressed on the surface of tumor cells, inducing tumor cell lysis and apoptosis through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP),